CRO with three decades in advancing innovative therapies will highlight new focus areas at annual Drug Information Association event
SAN DIEGO & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- Leaders from Synteract, an innovative contract research organization (CRO) providing full-service, Phase I-IV services to biopharma companies, will attend the annual DIA Conference in Boston, June 24-28, 2018. The company will exhibit its services in booth #1104. Executives will highlight the CRO’s established Centers of Development in oncology, neuro degenerative, rare and orphan disease, and pediatric studies, aligning the company’s notable expertise and clients’ needs in these areas.
Three Center of Development leaders will attend the conference, including:
- VP of Pediatric Development, Dr. Martine Dehlinger-Kremer, with 30 years of experience in the clinical research industry, can discuss growing requirements for medicines for children, how they will impact sponsors, and where gaps still exist. She has served as Chair of the Pediatric Working Group of EUCROF since 2008 and Chair of the European Forum for GCP (EFGCP) Children Medicines Working Party and is a member of Working Parties of Enpr-EMA, the European Network of Pediatric Research at the European Medicines Agency.
- VP of Neuro Degenerative Development, Linda Rawlings, can address challenges of clinical trials for neuro degenerative diseases, from drug compliance and accountability to patient consent and retention. Rawlings, MSc, FIBMS, draws on 27 years in the CRO, pharmaceutical and medical device sectors and more than a decade in operational and commercial roles, with a keen focus on developing and implementing strategies designed to deliver excellence at the local, international, and global level.
- VP of Rare and Orphan Disease Development, Lisa Dilworth, will discuss the uniqueness of treatments for rare and orphan diseases and how Synteract’s many years of experience, within many therapeutic indications, will guide sponsors who work in this area. Dilworth has more than 18 years of experience and has conducted research for indications such as Duchenne, spinal muscular atrophy, facioscapulohumeral MD, limb girdle MD, myasthenia gravis, retinitis pigmentosa and twin-to-twin transfusion syndrome, among others.
“Our therapeutic leadership have a wealth of experience and insights they bring to bear related to their focused areas of development. They are eager to share this and their broader industry knowledge in discussions with our clients while at DIA this year,” said CEO Steve Powell, who will also be in attendance. “We look forward to continuing to demonstrate how our operational excellence and deep therapeutic expertise can help our biopharmaceutical customers conduct the complex work they undertake in developing a better future for patients.”
Contact Melissa Hays, at Melissa.Hays@synteract.com, to set up an appointment.
Visit Synteract’s full schedule of events and follow its social channels on LinkedIn and Twitter for live updates during all conferences.
About Synteract
With 800 staff members across 21 countries, Synteract is an innovative, full-service contract research organization supporting biopharmaceutical companies in all phases of clinical development to help bring new medicines to market. Synteract has conducted nearly 4,000 studies on six continents and in more than 60 countries, working with more than 26,000 investigative sites and nearly 750,000 patients, contributing to more than 240 product approvals. The CRO offers a notable depth of expertise in oncology and neuro degenerative indications, as well as rare and orphan, pediatric, and immunotherapy studies.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180620005381/en/
